Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs FIBRONEER™ Ph3 trials in patients with IPF & other PF-ILDs Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
Why we may be more like our pets than we think Why we may be more like our pets than we think The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
Boehringer Ingelheim half-year results 2023 Boehringer Ingelheim half-year results 2023 First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Digital innovation: Our digital pipeline is only growing Digital innovation: Our digital pipeline is only growing BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
Animal Health Partnering Interests Pain & Mobility May 2024 CORP Animal Health Partnering Interests Pain & Mobility May 2024 CORP
supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf